tetano
Editor, Senior Moderator
J Infect Public Health
. 2022 Aug 27;15(10):1061-1064.
doi: 10.1016/j.jiph.2022.08.011. Online ahead of print.
Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
Rand A Alattar[SUP] 1 [/SUP], Shiema Abdalla[SUP] 1 [/SUP], Tasneem Abdallah[SUP] 2 [/SUP], Rashid Kazman[SUP] 3 [/SUP], Aseelah Qadmour[SUP] 3 [/SUP], Tawheeda Ibrahim[SUP] 2 [/SUP], Bassem Alhariri[SUP] 3 [/SUP], Shahd H Shaar[SUP] 1 [/SUP], Abeer Bajwa[SUP] 2 [/SUP], Abeir Alimam[SUP] 2 [/SUP], Rabia Qazi[SUP] 2 [/SUP], Fatma Ben Abid[SUP] 2 [/SUP], Joanne Daghfal[SUP] 1 [/SUP], Ali Eldeeb[SUP] 4 [/SUP], Kinda Shukri[SUP] 4 [/SUP], Ahmed Elsayed[SUP] 1 [/SUP], Fatima Rustom[SUP] 1 [/SUP], Musaed Alsamawi[SUP] 2 [/SUP], Alaaeldin Abdelmajid[SUP] 2 [/SUP], Miguel A P Basulto[SUP] 5 [/SUP], Armando A R Cobian[SUP] 5 [/SUP], Mohamed Abukhattab[SUP] 2 [/SUP], Abdullatif Alkhal[SUP] 2 [/SUP], Muna A Almaslamani[SUP] 2 [/SUP], Ali S Omrani[SUP] 6 [/SUP]
Affiliations
Abstract
We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1-3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
Keywords: Antiviral therapy; COVID-19; Favipiravir; Pneumonia; SARS-CoV-2.
. 2022 Aug 27;15(10):1061-1064.
doi: 10.1016/j.jiph.2022.08.011. Online ahead of print.
Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
Rand A Alattar[SUP] 1 [/SUP], Shiema Abdalla[SUP] 1 [/SUP], Tasneem Abdallah[SUP] 2 [/SUP], Rashid Kazman[SUP] 3 [/SUP], Aseelah Qadmour[SUP] 3 [/SUP], Tawheeda Ibrahim[SUP] 2 [/SUP], Bassem Alhariri[SUP] 3 [/SUP], Shahd H Shaar[SUP] 1 [/SUP], Abeer Bajwa[SUP] 2 [/SUP], Abeir Alimam[SUP] 2 [/SUP], Rabia Qazi[SUP] 2 [/SUP], Fatma Ben Abid[SUP] 2 [/SUP], Joanne Daghfal[SUP] 1 [/SUP], Ali Eldeeb[SUP] 4 [/SUP], Kinda Shukri[SUP] 4 [/SUP], Ahmed Elsayed[SUP] 1 [/SUP], Fatima Rustom[SUP] 1 [/SUP], Musaed Alsamawi[SUP] 2 [/SUP], Alaaeldin Abdelmajid[SUP] 2 [/SUP], Miguel A P Basulto[SUP] 5 [/SUP], Armando A R Cobian[SUP] 5 [/SUP], Mohamed Abukhattab[SUP] 2 [/SUP], Abdullatif Alkhal[SUP] 2 [/SUP], Muna A Almaslamani[SUP] 2 [/SUP], Ali S Omrani[SUP] 6 [/SUP]
Affiliations
- PMID: 36087547
- DOI: 10.1016/j.jiph.2022.08.011
Abstract
We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1-3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
Keywords: Antiviral therapy; COVID-19; Favipiravir; Pneumonia; SARS-CoV-2.